Studies have shown that JAK2 genomic amplification and increased expression occur specifically in TNBC, but not ER+ and HER2+ breast tumors, correlating with poor clinical outcomes such as progression-free survival and overall survival [76]. Here, JAK2 is linked to breast neoplasm.